Last edition
News about "Otsuka Pharmaceutical "
Otsuka's Voyxact Meets Key Phase 3 Endpoint in IgA Nephropathy Study
Otsuka presented new Phase 3 VISIONARY trial findings showing that Voyxact significantly slowed kidney function decline over two years, reinforcing its potential as a disease-modifying therapy for adults with primary IgA nephropathy.
Otsuka Pharmaceutical | 05/08/2026 | By News Bureau | 157
Otsuka Receives US FDA Approval for First-in-Class SIMTRIYO
The US Food and Drug Administration (FDA) has approved Otsuka's SIMTRIYO, the first Norepinephrine, Dopamine, Serotonin Reuptake Inhibitor (NDSRI) for treating ADHD in adults and children aged 6 years and older weighing at least 20 kg.
Otsuka Pharmaceutical | 27/07/2026 | By News Bureau
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Otsuka Pharmaceutical | 07/07/2026 | By News Bureau
Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy
Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.
Otsuka Pharmaceutical | 04/07/2026 | By News Bureau | 221
Cambridge Isotope Laboratories (CIL), a subsidiary of Japan’s Otsuka Pharmaceutical, has signed a Memorandum of Understanding (MoU) with Hyderabad-based Chemtatva Chiral Solutions (CCS) to establish a new entity — Cambridge Isotope Laboratories Pvt. Ltd. — in Hyderabad, India.
Otsuka Pharmaceutical | 29/10/2025 | By Dineshwori | 550
Cambridge Isotope Laboratories (CIL), a subsidiary of Otsuka Pharmaceutical (Japan), has launched ISOAPI-D, a unified brand of deuterated intermediates for active pharmaceutical ingredient (API) synthesis, at CPhI Frankfurt.
Otsuka Pharmaceutical | 29/10/2025 | By Dineshwori | 259
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy